BRNS
Barinthus Biotherapeutics plcNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$29.57M
P/E Ratio
—
EPS
$-1.29
Beta
-0.40
52W High
$2.91
52W Low
$0.51
50-Day MA
$0.65
200-Day MA
$0.83
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -336,000 |
| EBITDA | $-41.60M |
| Operating Margin | 0.00% |
| Return on Equity | -57.50% |
| Return on Assets | -23.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.63 |
| Price-to-Book | 0.45 |
| Price-to-Sales (TTM) | 3.80 |
| EV/Revenue | 0.616 |
| EV/EBITDA | -6.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $40.85M |
| Float | $27.26M |
| % Insiders | 19.81% |
| % Institutions | 44.30% |
Historical Volatility
HV 10-Day
90.09%
HV 20-Day
74.27%
HV 30-Day
64.19%
HV 60-Day
69.06%
HV Rank
22.6%
Volatility is currently expanding
More HEALTHCARE Stocks
Data last updated: 6/13/2026